In March 2013, we announced plans to establish a new Global R&D Centre and Corporate Headquarters in Cambridge on the Cambridge Biomedical Campus, the future home to approximately 2,000 employees. In February 2015, Cambridge City Council granted planning permission for our new site.
AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.
Address :
da Vinci Building Melbourn Science Park Melbourn
Post Code: SG8 6EE
Country: United Kingdom
Website: http://www.astrazeneca.co.uk
Membership Type: Enhanced Founder
Our skills focus on the discovery, development and commercialisation of medicines for the treatment of some of the world’s greatest healthcare challenges. Our commitment to making a meaningful difference in healthcare is founded on the pursuit of scientific excellence that addresses unmet patient need. Science is at the heart of AstraZeneca’s future strategy and success – and our aspiration is to achieve scientific leadership.
In March 2013, we announced our UK global R&D centre and corporate headquarters will be based at the Cambridge Biomedical Campus. The new, purpose-built site will be home to around 2000 highly-skilled staff, as part of our plan to create strategic global R&D centres in Britain, the United States and Sweden. This will bring together our small molecule and biologics activity, creating opportunities to capitalise on the promise of small and large molecule combinations, improving pipeline productivity and establishing AstraZeneca as a global leader in biopharmaceutical innovation.
The Biomedical Campus will also become our largest centre for oncology research, as well as hosting our work on cardiovascular and metabolic diseases, respiratory, inflammatory, autoimmune and nervous system conditions. Projects here will also include medicinal chemistry and high-throughput screening, and the facility will accommodate a number of pre-clinical research capabilities.
AstraZeneca has a long-standing presence in the UK and we're proud to be developing the next generation of medicines in Cambridge.
A global pharmaceutical company with a major UK presence. Through innovation and collaboration we can achieve better health for all.
The first participants have been dosed in a Phase I trial of AZD7442, a combination of two monoclonal antibodies (mAbs) in development for the prevention and treatment of COVID-19, reports AstraZeneca.
28-08-2020
AstraZeneca has concluded an agreement with the European Commission (EC) to supply up to 400 million doses of the AZD1222 COVID-19 vaccine.
18-08-2020
Potential new medicine DS-1062 could redefine treatment standards in lung, breast and multiple other cancers.
28-07-2020
AstraZeneca has reached an agreement with Europe’s Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 million doses of the University of Oxford’s COVID-19 vaccine, with deliveries starting by the end of 2020.
15-06-2020
AstraZeneca is advancing its ongoing response to address the unprecedented challenges of COVID-19, collaborating with a number of countries and multilateral organisations to make the University of Oxford’s potential vaccine widely accessible around the world in an equitable manner.
21-05-2020
AstraZeneca has developed valuable toolkits to help both leaders and employees effectively navigate through the COVID-19 crisis. Both toolkits are now available for download.
15-05-2020
AstraZeneca is joining forces with public research bodies and academic institutions as part of a UK government-led initiative to speed up the development of medicines to treat patients hospitalised with COVID-19.
30-04-2020
AstraZeneca and the University of Oxford today announced an agreement for the global development and distribution of the University’s potential recombinant adenovirus vaccine aimed at preventing COVID-19 infection from SARS-CoV-2.
30-04-2020
AstraZeneca delivered a quarter of strong revenue and profit growth, reflecting the immense efforts of supply-chain, commercial and other colleagues around the world to get vital medicines to patients. As part of the fight, the Company has rapidly responded to the pandemic, firstly in China and then globally.
29-04-2020
AstraZeneca will initiate a randomised, global clinical trial to assess the potential of Calquence (acalabrutinib), a blood cancer drug, in the treatment of the exaggerated immune response (cytokine storm) associated with COVID-19 infection in severely ill patients.
16-04-2020
AstraZeneca is joining forces with government and academia with the aim of discovering novel coronavirus-neutralising antibodies.
14-04-2020
AstraZeneca is donating nine million face masks to support healthcare workers around the world as they respond to the COVID-19 (novel coronavirus) global pandemic. AstraZeneca has partnered with the World Economic Forum’s COVID Action Platform, created with the support of the World Health Organisation, to identify countries in greatest need.
02-04-2020
St George Street Capital (SGSC), a UK registered charity, has signed a licence agreement with AstraZeneca to develop two compounds in the clinic: one for idiopathic male infertility, and the other for renal transplant rejection. The agreement enables additional compounds to be added in the future.
27-09-2019
Dr Jane Osbourn, Vice-President of Research and Development at AstraZeneca, has been made an Officer of the Order of the British Empire (OBE) in the Queen’s birthday honours list.
10-06-2019
AstraZeneca is hosting its second StartUP Science Competition for life science entrepreneurs in the Cambridge area.
08-05-2019
AstraZeneca and MSD Inc. have announced the European Commission has approved Lynparza (olaparib) for the treatment of germline BRCA-mutated HER2-negative advanced breast cancer.
12-04-2019
AstraZeneca's Forxiga is the first oral medicine approved in Europe as an adjunct to insulin for adults with type-1 diabetes and the first AstraZeneca medicine ever approved for type-1 diabetes.
27-03-2019
AstraZeneca and MedImmune, its global biologics research and development arm, will present 54 abstracts, including eight oral presentations and three late breakers, to the ESMO 2018 Congress (European Society for Medical Oncology) in Munich, Germany, 19-23 October.
11-10-2018
Are you an early-stage Cambridge start-up focused on life sciences/healthcare? Time is running out to enter AstraZeneca's first ever Start-Up Science competition for life science entrepreneurs in the Cambridge area.
25-05-2018
The Cambridge life sciences cluster has the potential to contribute an additional £1bn to the UK economy by 2032, according to independent research commissioned by AstraZeneca.
04-05-2018
Pages
There are no events to display
There are no jobs to display
No Blog articles found
